UNITED THERAPEUTICS CORP DEL ($UTHR)

1 tracked superinvestor hold UNITED THERAPEUTICS CORP DEL (UTHR), worth $1.1B combined, led by ex-Jim Simons. Smart money is trimming UTHR as of the latest 13F filings.

Current price

$552.48

Superinvestors holding

1

tracked 13F / N-PORT funds

Combined value

$1.1B

disclosed long exposure

Tier-1 conviction

0

concentrated holders

Net this quarter

-1

0 buying · 1 selling

Smart money is net reducing UTHR: 1 funds trimmed versus 0 adding.

The smart-money take on UTHR

UNITED THERAPEUTICS CORP DEL (UTHR) appears mainly in diversified and quant books here (1 funds, $1.1B combined) rather than in concentrated conviction portfolios — read the holders below with that in mind.

The largest position belongs to ex-Jim Simons at 1.7% of their book — no single tracked manager treats it as an outsized, top-weighted bet.

No tracked fund opened a new position this quarter; 0 added and 1 trimmed, a net reduction.

Superinvestors holding UTHR

InvestorMove% of their portfolioPosition value
2
ex-Jim Simons

Renaissance Technologies

Trimmed1.7%$1.1B

Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.

Frequently asked

Which superinvestors own UTHR?

1 tracked funds hold UNITED THERAPEUTICS CORP DEL (UTHR), the largest being ex-Jim Simons (Renaissance Technologies) at 1.7% of its 13F portfolio. 0 of them are concentrated Tier-1 conviction managers.

Is smart money buying or selling UTHR?

In the most recent 13F quarter, 0 tracked funds added or opened UTHR and 1 trimmed it.

How much UTHR do tracked funds hold?

Combined disclosed long exposure to UTHR across tracked superinvestors is $1.1B as of the Mar 2026 filings.

Stocks often held alongside UTHR

Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Mar 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.